Business Context and Reporting Period
This Form 8-K Current Report was filed by EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp.) on April 2, 2018, covering events occurring on March 27, 2018, and March 28, 2018. The filing primarily addresses executive compensation arrangements and a formal corporate name change.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation:
- Base Salary: $396,550 per year for the new Chief Medical Officer.
- Target Bonus: 35% of base salary.
- Severance: 12 months of base salary continuation plus one times the annual target bonus upon termination without cause or for good cause.
Material Changes
The following material changes were reported:
- Executive Appointment: Dario Paggiarino, M.D., was appointed as Vice President and Chief Medical Officer on March 27, 2018, under a new employment agreement.
- Corporate Name Change: The company changed its name from "pSivida Corp." to "EyePoint Pharmaceuticals, Inc." effective March 29, 2018.
- Trading Symbol Change: Common stock ceased trading under the ticker "PSDV" and commenced trading under "EYPT" on April 2, 2018.
- CUSIP Update: The company was assigned a new CUSIP number: 30233G100.
Outlook, Risks, and Contingencies
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond standard employment contract terms. Key contingencies include:
- Severance Conditions: Severance payments are contingent upon the executive executing a separation agreement with a general release of claims.
- Change of Control: Unvested options and restricted shares vest immediately upon termination following a change of control.
- Restrictive Covenants: The employment agreement includes 12-month non-competition and non-solicitation covenants following termination.
Investor Verification Checklist
- Verify the new ticker symbol "EYPT" and CUSIP "30233G100" for trading purposes.
- Review the full Employment Agreement (Exhibit to the upcoming Form 10-Q) for detailed definitions of "cause," "good cause," and "change of control."
- Confirm the impact of the name change on existing shareholder records and proxy materials.
- Monitor future filings for the company's first financial results under the new name and leadership structure.